Year All20262025 May 4, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 1, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 30, 2026 Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update March 30, 2026 Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease March 27, 2026 Vor Bio Announces $75 Million Private Placement with TCGX March 23, 2026 Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 23, 2026 Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference January 6, 2026 Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
March 30, 2026 Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 30, 2026 Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease